Omaha, NENCT07778316Now EnrollingIRB Ready

Small Cell Lung Cancer Clinical Trial in Omaha, NE

Access cutting-edge small cell lung cancer treatment through this phase 3 clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Omaha location

Preparing your pre-screening questions…

Expert Care in Omaha

Access small cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related small cell lung cancer treatment provided free

Apply for This Omaha Location

Check if you qualify for this small cell lung cancer clinical trial in Omaha, NE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Omaha

    Convenient for NE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Omaha site if eligible
  4. 4Begin participation

About This Small Cell Lung Cancer Study in Omaha

The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Participant has provided informed consent prior to initiation of any study specific activities/procedures.
Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
Participants who progressed or recurred following 1 platinum-based regimen.
Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
Minimum life expectancy of 12 weeks.
Adequate organ function.
History of central nervous system (CNS) metastases are allowed with considerations defined in the protocol.

Exclusion Criteria

Disease Related \- Any previous diagnosis of non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation that has transformed to SCLC, or mixed SCLC and NSCLC histology, with exceptions defined in the protocol. Other Medical Conditions
Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment.
History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
Current evidence or history of non-infectious pneumonitis/ILD (interstitial lung disease) that required steroids or other immunosuppressive treatment.
History of other malignancy within the past 2 years, with exceptions defined in the protocol.
Presence or history of viral infection based on criteria per protocol.
History of solid organ transplantation.
Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment.
Known sensitivity or a contraindication to any of the products or components.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Prior/Concomitant Therapy
Prior systemic anticancer therapy within 30 days of enrolment
Prior history of severe or life-threatening events from any immune-mediated therapy.
Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment.
Live and live-attenuated vaccines within 28 days prior to the start of study treatment.
Receiving another anticancer therapy for a malignancy other than SCLC.
More than 1 prior line of anticancer therapy for SCLC.
Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
Treatment in an alternative investigational trial within 28 days prior to enrolment.
History of allergy or hypersensitivity to similar products (eg, drugs with a similar chemical structure or other monoclonal antibody) or any excipient. Other Exclusions
Participants unable to have SC injections administered in the abdomen or thigh.
Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements.
History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT07778316) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Small Cell Lung Cancer Treatment Options in Omaha, NE

If you're searching for small cell lung cancer treatment options in Omaha, NE, this clinical trial (NCT07778316) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Omaha, NE

See all lung cancer clinical trials recruiting in Omaha — not just this study.

Browse Lung Cancer Trials in Omaha →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Omaha?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Omaha, NE